版本:
中国

BRIEF-Myriad Genetics publishes study evaluating its myPath melanoma test

April 5 Myriad Genetics Inc-

* Myriad Genetics -published third clinical validation study and second clinical utility study for its mypath melanoma test

* Myriad Genetics Inc says will submit reimbursement dossier to medicare and private insurers three months earlier than expected

* Myriad Genetics-3rd clinical validation study shows mypath melanoma test had overall diagnostic accuracy of 95 percent to differentiate melanoma from benign lesions Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐